NM Coordinating Committee: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
mNo edit summary |
||
| Line 14: | Line 14: | ||
::* [[PET_Amyloid_Biomarker_Ctte]] | ::* [[PET_Amyloid_Biomarker_Ctte]] | ||
::* [[SPECT_Biomarker_Ctte]] | ::* [[SPECT_Biomarker_Ctte]] | ||
::* TC99m Biomarker Committee [page coming soon] | |||
::* I-123 Biomarker Committee [page coming soon] | |||
==Meetings== | ==Meetings== | ||
* Tcons are held Quarterly. Contact the secretary for details. | * Tcons are held Quarterly. Contact the secretary for details. | ||
Revision as of 14:54, 11 July 2018
- Chairs: Richard Wahl, MD (Co-chair), Anne Smith, PhD (Co-chair), P. David Mozley, MD (Vice-chair)
- Secretary: Susan Stanfa (RSNA Staff)
Scope
The NM Coordinating Committee coordinates Biomarker Committees based on NM.
- Considering and proposing new candidate Biomarker Committees to the Steering Committee
- Preparing/Reviewing and Prioritizing groundwork funding proposals for submission to the Steering Committee
- Approving for publication Biomarker Profiles developed by the NM Biomarker Committees
- FDG-PET_Biomarker_Ctte
- PET_Amyloid_Biomarker_Ctte
- SPECT_Biomarker_Ctte
- TC99m Biomarker Committee [page coming soon]
- I-123 Biomarker Committee [page coming soon]
Meetings
- Tcons are held Quarterly. Contact the secretary for details.